121 related articles for article (PubMed ID: 18489407)
1. Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder cancer using a panel of biomarkers: a high-throughput tissue microarray analysis.
Pitts WR
BJU Int; 2008 Jun; 101(12):1595. PubMed ID: 18489407
[No Abstract] [Full Text] [Related]
2. Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: a high throughput tissue microarray analysis.
Mhawech-Fauceglia P; Fischer G; Alvarez V; Ahmed A; Herrmann FR
BJU Int; 2007 Nov; 100(5):1182-7. PubMed ID: 17645415
[TBL] [Abstract][Full Text] [Related]
3. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic factors and markers used in urothelial carcinoma of the bladder].
Billerey C; Vieillefond A
Ann Pathol; 1999; 19(5 Suppl):S107-9. PubMed ID: 10599469
[No Abstract] [Full Text] [Related]
5. Editorial comment on: Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder.
Joudi FN
Eur Urol; 2008 Mar; 53(3):579. PubMed ID: 17804153
[No Abstract] [Full Text] [Related]
6. P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells.
Mandeville JA; Silva Neto B; Vanni AJ; Smith GL; Rieger-Christ KM; Zeheb R; Loda M; Libertino JA; Summerhayes IC
BJU Int; 2008 Dec; 102(11):1707-14. PubMed ID: 18990147
[TBL] [Abstract][Full Text] [Related]
7. CD138-positive plasmacytoid urothelial carcinoma of the bladder.
Patriarca C; Di Pasquale M; Giunta P; Bergamaschi F
Int J Surg Pathol; 2008 Apr; 16(2):215-7. PubMed ID: 18417684
[No Abstract] [Full Text] [Related]
8. Invasive urothelial carcinoma with chordoid features: a report of 12 distinct cases characterized by prominent myxoid stroma and cordlike epithelial architecture.
Cox RM; Schneider AG; Sangoi AR; Clingan WJ; Gokden N; McKenney JK
Am J Surg Pathol; 2009 Aug; 33(8):1213-9. PubMed ID: 19542871
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis.
Vasala K; Pääkko P; Turpeenniemi-Hujanen T
Anticancer Res; 2008; 28(3B):1757-61. PubMed ID: 18630455
[TBL] [Abstract][Full Text] [Related]
10. How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions.
van der Kwast TH
Scand J Urol Nephrol Suppl; 2008 Sep; (218):175-84. PubMed ID: 18815932
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers in bladder cancer.
Bryan RT; Zeegers MP; James ND; Wallace DM; Cheng KK
BJU Int; 2010 Mar; 105(5):608-13. PubMed ID: 19793380
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of neuron-associated protein expression in non-muscle-invasive urothelial bladder cancer.
Mhawech-Fauceglia P; Ali L; Cheney RT; Groth J; Herrmann FR
J Clin Pathol; 2009 Aug; 62(8):710-4. PubMed ID: 19638542
[TBL] [Abstract][Full Text] [Related]
14. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
[TBL] [Abstract][Full Text] [Related]
15. Plasmacytoid urothelial carcinoma of the urinary bladder: a case report and immunohistochemical study.
Sato K; Ueda Y; Kawamura K; Aihara K; Katsuda S
Pathol Res Pract; 2009; 205(3):189-94. PubMed ID: 19041193
[TBL] [Abstract][Full Text] [Related]
16. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder.
Xylinas E; Kluth LA; Lotan Y; Daneshmand S; Rieken M; Karakiewicz PI; Shariat SF
Urol Oncol; 2014 Apr; 32(3):230-42. PubMed ID: 24332648
[TBL] [Abstract][Full Text] [Related]
17. Bladder cancer: modeling and translation.
Rosenberg JE; Hahn WC
Genes Dev; 2009 Mar; 23(6):655-9. PubMed ID: 19299556
[TBL] [Abstract][Full Text] [Related]
18. Considerations on the use of urine markers for bladder cancer.
van Rhijn BW
Eur Urol; 2008 May; 53(5):880-1. PubMed ID: 18222604
[No Abstract] [Full Text] [Related]
19. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in urothelial carcinoma of the bladder: histologic and molecular correlates.
Solomon JP; Hansel DE
Adv Anat Pathol; 2015 Mar; 22(2):102-12. PubMed ID: 25664945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
